

EMA/706319/2021

European Medicines Agency decision P/0534/2021

of 6 December 2021

on the acceptance of a modification of an agreed paediatric investigation plan for pembrolizumab (Keytruda), (EMA-001474-PIP02-16-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0534/2021

of 6 December 2021

on the acceptance of a modification of an agreed paediatric investigation plan for pembrolizumab (Keytruda), (EMA-001474-PIP02-16-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0204/2016 issued on 1 August 2016 and the decision P/0008/2018 issued on 30 January 2018,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc on 6 August 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 November 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pembrolizumab (Keytruda), concentrate for solution for infusion, powder for concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0059/2014 issued on 7 March 2014, including subsequent modifications thereof.

Article 3

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., Clos du Lynx 5, Binnenhof, B-1200 – Brussels, Belgium.

EMA/PDCO/461185/2021
Amsterdam, 12 November 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001474-PIP02-16-M02

Scope of the application

Active substance(s):

Pembrolizumab

Invented name:

Keytruda

Condition(s):

Treatment of Hodgkin lymphoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for solution for infusion

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc submitted to the European Medicines Agency on 6 August 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European

Medicines Agency's decision P/0204/2016 issued on 1 August 2016 and the decision P/0008/2018 issued on 30 January 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 14 September 2021.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of Hodgkin lymphoma

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- concentrate for solution for infusion and powder for concentrate for solution, for intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of Hodgkin lymphoma

2.1.1. Indication(s) targeted by the PIP

- Treatment of classical Hodgkin lymphoma with incomplete early response to front-line chemotherapy in children from 3 years to less than 18 years of age
- Treatment of relapsed or refractory classical Hodgkin lymphoma in children from 5 years to less than 18 years of age

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

- Concentrate for solution for infusion
- Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable

Clinical studies	2	Study 1 Multi-centre, open-label, single-arm trial to evaluate pharmacokinetics, pharmacodynamics, toxicity, safety and activity of pembrolizumab in paediatric patients from 6 months to less than 18 years with an advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumour or lymphoma, including an expansion phase (same as study 2 in EMEA-001474-PIP01-13) Study 2 Open-label, non-controlled trial to evaluate the safety and efficacy of pembrolizumab in combination with chemotherapy in paediatric patients from 3 years to less than 18 years of age (and young adults) with a classical Hodgkin with incomplete early response to front-line therapy
Extrapolation, modelling & simulation studies	0	Not applicable
Other studies	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

- KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.
- KEYTRUDA, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS $\geq$ 10.

Authorised pharmaceutical form(s):

Powder for concentrate for solution for infusion

Concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use